Adjuvant Chemotherapy Administration and Survival Outcomes in Lymphoma Survivors with Common Solid Tumors: A Population-Based Study

Conclusions: In most studied scenarios, despite prior exposure to intensive chemotherapy, survivors of DLBCL or HL received adjuvant chemotherapy for common cancers at similar rates relative to patients with no history of lymphoma. Therefore, contrary to prior suggestions, differences in application of chemotherapy cannot explain survival disparities between lymphoma survivors and other patients with the same cancers. HL survivors had consistently worse OS even in the subpopulation receiving chemotherapy, suggesting that other (e.g. cardiovascular) sources of mortality related to late toxicities of HL treatment may be contributing, rather than differences in treatment. Unique survival patterns among DLBCL survivors suggest that limits on anthracycline-based chemotherapy due to cumulative lifetime dosing may impair outcomes in breast cancer, but not in cancers like colon or lung, which are treated with non-overlapping taxane- or fluorouracil-based adjuvant regimens.DisclosuresOlszewski: Genentech: Research Funding; TG Therapeutics: Research Funding; Spectrum Pharmaceuticals: Consultancy, Research Funding.
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions: Outcomes in Lymphoid Malignancies and Stem Cell Transplant Source Type: research